• Molecular NameUracil mustard
  • SynonymNA
  • Weight252.101
  • Drugbank_IDDB00791
  • ACS_NO66-75-1
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.38
  • pkaN/A
  • LogD (pH=7, predicted)0.37
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.07
  • LogSw (predicted, AB/LogsW2.0)2.47
  • Sw (mg/ml) (predicted, ACD/Labs)0.21
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds5
  • TPSA61.44
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA chemotherapy drug which belongs to the class of alkylating agents. It is used in lymphatic malignancies such as non-Hodgkin's lymphoma. It works by damaging DNA, primarily in cancer cells that preferentially take up the uracil due to their need to make nucleic acids during their rapid cycles of cell division. The DNA damage leads to apoptosis of the affected cells. Bone marrow suppression and nausea are the main side effects.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding5.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A